A new innovative wearable patch has been created to detect early signs of the deadliest form of skin cancer. This wireless device enables individuals to conduct self-screening at home, potentially identifying melanoma sooner and lowering the need for unnecessary biopsies, as per researchers.
Developed by American scientists, the battery-free patch aims to make screening more convenient and less intrusive. They emphasized that skin cancer, especially melanoma, poses a significant threat among various types of the disease.
Melanoma UK estimates that over 19,000 individuals in the UK will receive a melanoma diagnosis by 2025. Timely detection plays a critical role in successful treatment, but existing methods primarily rely on visual examination, which can be subjective and miss crucial early signs.
Unlike more advanced diagnostic methods available only in specialized clinics, the new patch, spearheaded by Dr. Mohammad Moghimi, measures the bioimpedance of skin lesions in a straightforward and non-invasive manner. Bioimpedance reflects how electrical signals move through living tissue.
Cancerous regions often exhibit distinct electrical characteristics compared to healthy skin. Through bioimpedance measurements, the patch can help pinpoint ‘abnormal’ areas requiring further medical assessment.
The research team at Wake Forest University School of Medicine in North Carolina designed a flexible, chip-less, and battery-free patch that adheres directly to the skin and communicates wirelessly with a small reader device. To evaluate its efficacy, 10 volunteers participated, with the patch applied to both pigmented skin lesions and adjacent healthy skin areas.
Utilizing safe electrical signals to gauge bioimpedance, the patch revealed ‘significant’ variances between healthy and abnormal skin. Published in Biomedical Innovations, the study illustrated the patch’s ability to clearly differentiate between healthy skin and potentially concerning spots.
It successfully detected distinctive electrical signals from suspicious moles or lesions irrespective of skin tone. Dr. Moghimi, the principal investigator, emphasized the importance of early detection in treating skin cancer and the patch’s potential to empower patients and primary care providers for timely intervention.
Distinguished by its battery-free and chip-less design, the patch is lightweight, disposable, and cost-effective. It offers objective numerical data about skin health, reducing unnecessary biopsies and aiding doctors in making informed decisions.
In addition to providing supplementary insights into lesions, the patch complements other diagnostic techniques like imaging-based methods. It is also effective across all skin tones, capable of identifying changes in small or visually ambiguous lesions.
Dr. Moghimi, an Assistant Professor of biomedical engineering at Wake Forest, highlighted the accessibility goal for early skin cancer detection through the patch. Plans include enhancing the patch with conductive hydrogel electrodes for improved performance and comfort.
Future endeavors involve larger clinical studies to assess the patch’s real-world effectiveness and its ability to differentiate between benign and malignant lesions accurately.